Trial Profile
A Randomized, Placebo-controlled, Single Center, 5 Cohort Dose Escalation Trial to Investigate Safety and Pharmacokinetics of rVIIa-FP (CSL689) in Comparison to Placebo in Healthy Male Human Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Apr 2017
Price :
$35
*
At a glance
- Drugs CSL 689 (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions
- Sponsors CSL Behring
- 12 Jun 2014 New trial record